Cargando…

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

BACKGROUND: One of the major challenges in currently chemotherapeutic theme is lacking effective biomarkers for drug response and sensitivity. Our current study focus on two promising biomarkers, ERCC1 (excision repair cross-complementing group 1) and BRCA1 (breast cancer susceptibility gene 1). To...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Lifeng, Wei, Jia, Qian, Xiaoping, Yin, Haitao, Zhao, Yang, Yu, Lixia, Wang, Tingting, Liu, Baorui
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394535/ https://www.ncbi.nlm.nih.gov/pubmed/18402708 http://dx.doi.org/10.1186/1471-2407-8-97

Ejemplares similares

Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions
por: Xie, Li, et al.
Publicado: (2010)

BRCA1 mRNA Expression as a Predictive and Prognostic Marker in Advanced Esophageal Squamous Cell Carcinoma Treated with Cisplatin- or Docetaxel-Based Chemotherapy/Chemoradiotherapy
por: Gao, Yong, et al.
Publicado: (2013)

ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin
por: Tiseo, M, et al.
Publicado: (2013)

BRCA1 and ERCC1 mRNA levels are associated with lymph node metastasis in Chinese patients with colorectal cancer
por: Yuanming, Lu, et al.
Publicado: (2013)

Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer
por: Shen, Jie, et al.
Publicado: (2014)

Synergistic anti-proliferative effects of gambogic acid with docetaxel in gastrointestinal cancer cell lines
por: Zou, Zhengyun, et al.
Publicado: (2012)

The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients
por: Obiedat, Hadeel, et al.
Publicado: (2018)

Joint detection of ERCC1, TUBB3, and TYMS guidance selection of docetaxel, 5-fluorouracil and cisplatin (DDP) individual chemotherapy in advanced gastric cancer patients
por: Luo, Yushuang, et al.
Publicado: (2014)

The Expression of ERCC1, RRM1, and BRCA1 in Breast Cancer According to the Immunohistochemical Phenotypes
por: Kim, Dokyung, et al.
Publicado: (2011)

ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy
por: Xian-jun, Feng, et al.
Publicado: (2014)

Meta-Analysis of ERCC1 Protein Expression and Platinum Chemosensitivity in Non-Small-Cell Lung Cancer
por: Li, Guoping, et al.
Publicado: (2020)

CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients
por: Park, S R, et al.
Publicado: (2011)

BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer Cells
por: Horiuchi, Akiko, et al.
Publicado: (2007)

The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
por: Song, Wenhui, et al.
Publicado: (2016)

The deacetylation of Foxk2 by Sirt1 reduces chemosensitivity to cisplatin
por: Wang, Xi‐wen, et al.
Publicado: (2021)

Retraction Note: Joint detection of ERCC1, TUBB3, and TYMS guidance selection of docetaxel, 5-fluorouracil and cisplatin (DDP) individual chemotherapy in advanced gastric cancer patients
por: Luo, Yushuang, et al.
Publicado: (2015)

BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells
por: Tassone, P, et al.
Publicado: (2003)

ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma
por: Bai, Zhou-lan, et al.
Publicado: (2012)

Microarray gene expression analysis of chemosensitivity for docetaxel, cisplatin and 5-fluorouracil (TPF) combined chemotherapeutic regimen in hypopharyngeal squamous cell carcinoma
por: Lian, Meng, et al.
Publicado: (2017)

Effects of NOB1 on the pathogenesis of osteosarcoma and its expression on the chemosensitivity to cisplatin
por: Luo, Leiming, et al.
Publicado: (2018)

Chemosensitizing effect of shRNA-mediated ERCC1 silencing on a Xuanwei lung adenocarcinoma cell line and its clinical significance
por: Wang, Weiwei, et al.
Publicado: (2017)

Relevance of ERCC1, RRM1 and BRCA1 in surgically treated non-small cell lung cancer patients
por: Pesta, Martin, et al.
Publicado: (2014)

Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer
por: Takayama, T, et al.
Publicado: (2007)

A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine
por: Lee, Keun-Wook, et al.
Publicado: (2017)

DNA Repair Genes ERCC1 and BRCA1 Expression in Non-Small Cell Lung Cancer Chemotherapy Drug Resistance
por: Wang, Shuai, et al.
Publicado: (2016)

Cell fate determination in cisplatin resistance and chemosensitization
por: Luong, Khanh V., et al.
Publicado: (2016)

The effects of BRCA1 expression on the chemosensitivity of gastric cancer cells to platinum agents
por: Kim, Geon, et al.
Publicado: (2019)

ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis
por: Zhang, Yuqiang, et al.
Publicado: (2021)

ERCC1 and ERCC2 Variants Predict Survival in Gastric Cancer Patients
por: Li, Yangkai, et al.
Publicado: (2013)

Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer
por: Papadaki, C, et al.
Publicado: (2011)

The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC
por: Cai, Yang, et al.
Publicado: (2015)

MiR-192-5p reverses cisplatin resistance by targeting ERCC3 and ERCC4 in SGC7901/DDP cells
por: Xie, Xiaoque, et al.
Publicado: (2019)

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
por: Wilbur, H. Catherine, et al.
Publicado: (2023)

RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin
por: Muñoz-Montaño, Wendy, et al.
Publicado: (2021)

Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
por: Sun, Xue-Song, et al.
Publicado: (2020)

Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer
por: Du, Juan, et al.
Publicado: (2022)

Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)
por: Osorio, A, et al.
Publicado: (2009)

Association of ERCC1 rs3212986 & ERCC2 rs13181 polymorphisms with the risk of glioma
por: Cui, Qing-ke, et al.
Publicado: (2014)

ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer
por: Choueiri, Michel B., et al.
Publicado: (2015)

Outcome Definition Influences the Relationship between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients
por: Zazuli, Zulfan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b758693qbo54lj82m6gi9ojgqj